Articles related to FDA

The FDA’s accelerated approval of elranatamab offers a new therapeutic pathway for adults with relapsed or refractory multiple myeloma. With promising response rates and an established safety profile, this treatment may provide a much-needed option for those struggling with relapsed myeloma.

The updated prescribing guidelines for Wegovy (semaglutide) offer new maintenance dosing options for adults, reflecting recent research findings.

The FDA’s approval of Zurzuvae (zuranolone) as the first oral treatment for postpartum depression represents a significant advancement in patient care. Physicians are encouraged to explore this new option, considering both its proven efficacy and accompanying warnings, to provide more accessible care for those struggling with this serious condition.

The recent FDA approval of cantharidin introduces a novel topical treatment for molluscum contagiosum in patients aged 2 and above, presenting a significant stride in dermatological solutions.

The DEA and FDA are addressing the current prescription stimulant shortage, emphasizing both the importance of patient access and the need for responsible prescribing. Stay informed on the latest updates and consider alternative treatments where appropriate.

The FDA’s approval of the olaparib, abiraterone, and prednisone regimen for BRCA-mutated mCRPC, based on the PROpel trial, could significantly alter the treatment landscape. Learn more about this promising development in prostate cancer therapy.